Interestingly, METTL3 within CAFs orchestrates IL-18 expression through m6A-mediated mRNA modification, thereby triggering NF-κB signaling to modulate PD-L1-dependent immunosuppression in non-small cell lung cancer. Here, METTL3 is linked to non-small cell lung carcinoma.